These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
746 related articles for article (PubMed ID: 36699466)
41. A New Prognostic Indicator of Immune Microenvironment and Therapeutic Response in Lung Adenocarcinoma Based on Peroxisome-Related Genes. Xiong Z; Zhang L; Fan W J Immunol Res; 2022; 2022():6084589. PubMed ID: 35935579 [TBL] [Abstract][Full Text] [Related]
42. A novel pyroptosis related genes signature for predicting prognosis and estimating tumor immune microenvironment in lung adenocarcinoma. Wu C; Zhao J; Wang X; Wang Y; Zhang W; Zhu G Transl Cancer Res; 2022 Aug; 11(8):2647-2659. PubMed ID: 36093538 [TBL] [Abstract][Full Text] [Related]
43. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis. Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111 [No Abstract] [Full Text] [Related]
44. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis. Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J Front Immunol; 2022; 13():783495. PubMed ID: 35222371 [TBL] [Abstract][Full Text] [Related]
45. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma. Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454 [TBL] [Abstract][Full Text] [Related]
46. Apoptosis-Related Signature Predicts Prognosis and Immune Microenvironment Infiltration in Lung Adenocarcinoma. Zou X; He R; Zhang Z; Yan Y Front Genet; 2022; 13():818403. PubMed ID: 35571020 [TBL] [Abstract][Full Text] [Related]
47. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma. Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D Front Immunol; 2023; 14():1181370. PubMed ID: 37600770 [TBL] [Abstract][Full Text] [Related]
48. Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma. Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J Cancer Immunol Immunother; 2021 Dec; 70(12):3651-3667. PubMed ID: 33977344 [TBL] [Abstract][Full Text] [Related]
49. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients. Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714 [TBL] [Abstract][Full Text] [Related]
50. [Construction and Validation of Prognostic Risk Score Model of Autophagy Related Genes in Lung Adenocarcinoma]. Zhou J; Wang X; Li Z; Jiang R Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):557-566. PubMed ID: 34256900 [TBL] [Abstract][Full Text] [Related]
51. A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma. Ouyang W; Jiang Y; Bu S; Tang T; Huang L; Chen M; Tan Y; Ou Q; Mao L; Mai Y; Yao H; Yu Y; Lin X Front Cell Dev Biol; 2021; 9():758777. PubMed ID: 35141229 [No Abstract] [Full Text] [Related]
52. Evaluating the Prognostic and Therapeutic Potentials of the Proteasome 26S Subunit, ATPase ( Ullah MA; Islam NN; Moin AT; Park SH; Kim B Front Genet; 2022; 13():935286. PubMed ID: 35938038 [TBL] [Abstract][Full Text] [Related]
53. Identification of a novel autophagy signature for predicting survival in patients with lung adenocarcinoma. Duan J; Lei Y; Lv G; Liu Y; Zhao W; Yang Q; Su X; Song Z; Lu L; Shi Y PeerJ; 2021; 9():e11074. PubMed ID: 33976960 [TBL] [Abstract][Full Text] [Related]
54. An Han Y; Wong FC; Wang D; Kahlert C Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555 [TBL] [Abstract][Full Text] [Related]
55. Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes. Hua L; Wu J; Ge J; Li X; You B; Wang W; Hu B Front Cell Dev Biol; 2023; 11():1060086. PubMed ID: 37234773 [No Abstract] [Full Text] [Related]
56. IL-1 receptor-associated kinase 3 (IRAK3) in lung adenocarcinoma predicts prognosis and immunotherapy resistance: involvement of multiple inflammation-related pathways. Zhou Y; Rao W; Li Z; Guo W; Shao F; Zhang Z; Zhang H; Liu T; Li Z; Tan F; Xue Q; Gao S; He J Transl Lung Cancer Res; 2024 Sep; 13(9):2139-2161. PubMed ID: 39430338 [TBL] [Abstract][Full Text] [Related]
57. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes. Li F; Niu Y; Zhao W; Yan C; Qi Y Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857 [TBL] [Abstract][Full Text] [Related]
58. Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes. Duan G; Huang C; Zhao J; Zhang Y; Zhao W; Dai H Sci Rep; 2023 Nov; 13(1):20930. PubMed ID: 38017020 [TBL] [Abstract][Full Text] [Related]
59. Establishment of a prognostic signature for lung adenocarcinoma by integration of 7 pyroptosis-related genes and cross-validation between the TCGA and GEO cohorts: A comprehensive bioinformatics analysis. Zhang W; Wan S; Qu Z; Ge J; Zhang C; Li C; Jiang Y Medicine (Baltimore); 2022 Jul; 101(29):e29710. PubMed ID: 35866781 [TBL] [Abstract][Full Text] [Related]
60. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma. Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]